Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27561167 | 0.95 | KEAP1 (0.40) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL4470158 | 0.78 | KEAP1 (0.44) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL12019802 | 0.77 | CYP19A1 (0.34) | — | |
| SCHEMBL28259607 | 0.77 | KEAP1 (0.38) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL13785560 | 0.76 | KEAP1 (0.46) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL198459 | 0.75 | MAPT (0.52) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL12531908 | 0.75 | MAPT (0.52) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL846064 | 0.75 | KEAP1 (0.48) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL27432645 | 0.75 | KEAP1 (0.48) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL27819590 | 0.75 | CHRM2 (0.40) | KEAP1NFE2L2CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252574-A1 | PROCESSES FOR THE PREPARATION OF O-DESMETHYLVENLAFAXINE, FREE FROM ITS DIMER IMPURITIES | Teva Pharmaceutical Industries Ltd. (IL) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009151494-A1 | PROCESSES FOR THE PREPARATION OF O-DESMETHYLVENLAFAXINE, FREE FROM ITS DIMER IMPURITIES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-12-17 | — | — | WO | disclosed |
| US-7605290-B2 | Processes for the synthesis of O-desmethylvenlafaxine | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-10-20 | — | — | US | disclosed |
| US-20090234020-A1 | Processes for the preparation of odesmethylvenlafaxine, free from its dimer impurities | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2009-09-17 | — | — | US | disclosed |
| WO-2009073066-A1 | PROCESSES FOR THE SYNTHESIS OF O-DESMETHYLVENLAFAXINE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-06-11 | — | — | WO | disclosed |
| US-20090137846-A1 | Processes for the synthesis of O-Desmethylvenlafaxine | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2009-05-28 | — | — | US | disclosed |
| EP-2046725-A2 | PROCESSES FOR THE SYNTHESIS OF O-DESMETHYLVENLAFAXINE | Teva Pharmaceutical Industries Ltd. (IL) | 2009-04-15 | — | — | EP | disclosed |
| US-20090069601-A1 | Processes for the synthesis of O-desmethylvenlafaxine | TEVA PHARMACEUTICALS USA, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090062572-A1 | Processes for the synthesis of O-desmethylvenlafaxine | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-05 | — | — | US | disclosed |
| EP-2007708-A1 | SUBSTANTIALLY PURE O-DESMETHYLVENLAFAXINE AND PROCESSES FOR PREPARING IT | Teva Pharmaceutical Industries Ltd (IL) | 2008-12-31 | — | — | EP | disclosed |
| EP-1934167-A2 | PROCESSES FOR THE SYNTHESIS OF O-DESMETHYLVENLAFAXINE | Teva Pharmaceutical Industries Ltd. (IL) | 2008-06-25 | — | — | EP | disclosed |
| US-20080139849-A1 | Processes for the synthesis of O-desmethylvenlafaxine | TEVA PHARMACEUTICALS USA, INC. | 2008-06-12 | — | — | US | disclosed |
| EP-1917237-A2 | PROCESSES FOR THE SYNTHESIS OF O-DESMETHYLVENLAFAXINE | Teva Pharmaceutical Industries Ltd (IL) | 2008-05-07 | — | — | EP | disclosed |
| WO-2008013990-A2 | PROCESSES FOR THE SYNTHESIS OF O-DESMETHYLVENLAFAXINE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008013993-A2 | PROCESSES FOR THE SYNTHESIS OF O-DESMETHYLVENLAFAXINE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008013995-A2 | TRIDESMETHYLVENLAFAXINE AND PROCESSES FOR THE SYNTHESIS OF O-DESMETHYLVENLAFAXINE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008013994-A2 | PROCESSES FOR THE SYNTHESIS OF O-DESMETHYLVENLAFAXINE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-01-31 | — | — | WO | disclosed |
| US-20080015259-A1 | Substantially pure O-desmethylvenlafaxine and processes for preparing it | TEVA PHARMACEUTICALS USA, INC. | 2008-01-17 | — | — | US | disclosed |
| WO-2007120923-A1 | SUBSTANTIALLY PURE O-DESMETHYLVENLAFAXINE AND PROCESSES FOR PREPARING IT | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-10-25 | — | — | WO | disclosed |
| US-4136188-A | TREATMENT OF DIABETES WITH 2-SUBSTITUTED-1,3-DIAZACYCLIC COMPOUNDS | DAIICHI SEIYAKU CO., LTD. (JP) | 1979-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234020-A1 | Processes for the preparation of odesmethylvenlafaxine, free from its dimer impurities | CYP2D6, OGFR, DHFR | KEAP1 4716/4885NFE2L2 3320/4885CHRM3 2106/4885 |
| US-20090062572-A1 | Processes for the synthesis of O-desmethylvenlafaxine | CYP2D6, MAOB, CYP2C9 | KEAP1 1601/4885NFE2L2 1852/4885CHRM3 1504/4885 |
| US-20080139849-A1 | Processes for the synthesis of O-desmethylvenlafaxine | CYP2D6, CYP4F3, CYP3A5 | KEAP1 1993/4885NFE2L2 2040/4885CHRM3 1928/4885 |
| US-20090069601-A1 | Processes for the synthesis of O-desmethylvenlafaxine | CYP2D6, CYP4F3, CYP3A5 | KEAP1 1993/4885NFE2L2 2040/4885CHRM3 1928/4885 |
| US-20080015259-A1 | Substantially pure O-desmethylvenlafaxine and processes for preparing it | CYP2F1, COMT, CYP2D6 | KEAP1 3266/4885NFE2L2 2925/4885CHRM3 1781/4885 |
| US-20090137846-A1 | Processes for the synthesis of O-Desmethylvenlafaxine | CYP2D6, CYP4F3, CYP3A5 | KEAP1 1993/4885NFE2L2 2040/4885CHRM3 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.